These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 12761331)

  • 1. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.
    Setola V; Hufeisen SJ; Grande-Allen KJ; Vesely I; Glennon RA; Blough B; Rothman RB; Roth BL
    Mol Pharmacol; 2003 Jun; 63(6):1223-9. PubMed ID: 12761331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.
    Fitzgerald LW; Burn TC; Brown BS; Patterson JP; Corjay MH; Valentine PA; Sun JH; Link JR; Abbaszade I; Hollis JM; Largent BL; Hartig PR; Hollis GF; Meunier PC; Robichaud AJ; Robertson DW
    Mol Pharmacol; 2000 Jan; 57(1):75-81. PubMed ID: 10617681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
    Rothman RB; Baumann MH; Savage JE; Rauser L; McBride A; Hufeisen SJ; Roth BL
    Circulation; 2000 Dec; 102(23):2836-41. PubMed ID: 11104741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells.
    Jones DC; Lau SS; Monks TJ
    J Pharmacol Exp Ther; 2004 Oct; 311(1):298-306. PubMed ID: 15169827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions.
    Bankson MG; Cunningham KA
    J Pharmacol Exp Ther; 2001 Jun; 297(3):846-52. PubMed ID: 11356903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease.
    Droogmans S; Cosyns B; D'haenen H; Creeten E; Weytjens C; Franken PR; Scott B; Schoors D; Kemdem A; Close L; Vandenbossche JL; Bechet S; Van Camp G
    Am J Cardiol; 2007 Nov; 100(9):1442-5. PubMed ID: 17950805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An assessment of the acute effects of the serotonin releasers methylenedioxymethamphetamine, methylenedioxyamphetamine and fenfluramine on immunity in rats.
    Connor TJ; Kelly JP; Leonard BE
    Immunopharmacology; 2000 Mar; 46(3):223-35. PubMed ID: 10741902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The fenfluramine metabolite (+)-norfenfluramine is vasoactive.
    Ni W; Li MW; Thakali K; Fink GD; Watts SW
    J Pharmacol Exp Ther; 2004 May; 309(2):845-52. PubMed ID: 14752059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations.
    Bowyer JF; Young JF; Slikker W; Itzak Y; Mayorga AJ; Newport GD; Ali SF; Frederick DL; Paule MG
    Neurotoxicology; 2003 Jun; 24(3):379-90. PubMed ID: 12782103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [3,4-methylenedioxymethamphetamine ('ecstasy'): its long-term emotional and cognitive effects, and serotonin depletion].
    Molero-Chamizo A
    Rev Neurol; 2005 Jul 16-31; 41(2):108-14. PubMed ID: 16028190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor.
    Setola V; Dukat M; Glennon RA; Roth BL
    Mol Pharmacol; 2005 Jul; 68(1):20-33. PubMed ID: 15831837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonergic drugs and valvular heart disease.
    Rothman RB; Baumann MH
    Expert Opin Drug Saf; 2009 May; 8(3):317-29. PubMed ID: 19505264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic and adverse actions of serotonin transporter substrates.
    Rothman RB; Baumann MH
    Pharmacol Ther; 2002 Jul; 95(1):73-88. PubMed ID: 12163129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 5-hydroxytryptamine2A receptor is involved in (+)-norfenfluramine-induced arterial contraction and blood pressure increase in deoxycorticosterone acetate-salt hypertension.
    Ni W; Fink GD; Watts SW
    J Pharmacol Exp Ther; 2007 May; 321(2):485-91. PubMed ID: 17289838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effects of benfluorex on heart valves and pulmonary circulation.
    Szymanski C; Andréjak M; Peltier M; Maréchaux S; Tribouilloy C
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):679-86. PubMed ID: 24817577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters.
    Rothman RB; Clark RD; Partilla JS; Baumann MH
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1191-9. PubMed ID: 12649307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ecstasy induces apoptosis via 5-HT(2A)-receptor stimulation in cortical neurons.
    Capela JP; Fernandes E; Remião F; Bastos ML; Meisel A; Carvalho F
    Neurotoxicology; 2007 Jul; 28(4):868-75. PubMed ID: 17572501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the behavioral and neurochemical effects of 5,7-DHT, MDMA and D,L-fenfluramine.
    Lorens SA; Hata N; Cabrera T; Hamilton ME
    NIDA Res Monogr; 1989; 95():347. PubMed ID: 2577039
    [No Abstract]   [Full Text] [Related]  

  • 19. Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat.
    Morley KC; Arnold JC; McGregor IS
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jun; 29(5):648-57. PubMed ID: 15908091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
    McNamara R; Kerans A; O'Neill B; Harkin A
    Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.